COAST : An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer
-
Herbst, Roy S. (Yale Cancer Center. Smilow Cancer Hospital)
;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Barlesi, Fabrice (Gustave Roussy) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Chu, Quincy (Cross Cancer Institute) ;
Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ;
Sánchez Hernández, Alfredo (Consorci Hospitalari Provincial de Castelló) ;
Dakhil, Shaker (Cancer Center of Kansas) ;
Camidge, D (University of Colorado Anschutz Medical Campus) ;
Winzer, Leanne (AstraZeneca) ;
Soo-Hoo, Yee (AstraZeneca) ;
Cooper, Zachary A. (AstraZeneca) ;
Kumar, Rakesh (AstraZeneca) ;
Bothos, John (AstraZeneca) ;
Aggarwal, Charu (Abramson Cancer Center. University of Pennsylvania) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia)
visitante ::
identificación
Subscribirse to this discussion. You will then receive all new comments by email.
